KAZIA THERAPEUTICS LIMITED

Highlights Kazia Therapeutics Limited

Equities

KZIA

US48669G1058

Market Closed - Nasdaq Other stock markets 21:30:01 24/05/2024 BST			5-day change	1st Jan Change
0.2793 ^USD	+3.44%		+1.56%	-36.45%

05-01	Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients	CI
04-19	Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients	05-01	CI
Kazia Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	03-27	CI
Kazia Therapeutics Limited Enters into an Exclusive Licensing Agreement Withsovargen Co., Ltd	03-21	CI
Kazia Therapeutics' Lead Drug Candidate Meets Goal of Early-Stage Study	02-21	MT
Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint	02-21	CI
Kazia Announces Non-Binding Letter of Intent for the Proposed Granting of Rights to Develop and Commercialize Paxalisib Outside of Oncology	11-29	CI
Kazia Therapeutics Signs Letter of Intent for Rights Licensing Deal	11-29	MT
Kazia Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer